AR059089A1 - Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal - Google Patents

Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal

Info

Publication number
AR059089A1
AR059089A1 ARP070100239A ARP070100239A AR059089A1 AR 059089 A1 AR059089 A1 AR 059089A1 AR P070100239 A ARP070100239 A AR P070100239A AR P070100239 A ARP070100239 A AR P070100239A AR 059089 A1 AR059089 A1 AR 059089A1
Authority
AR
Argentina
Prior art keywords
storage diseases
enzyme
lisosomal
intraventricular administration
lysosomal storage
Prior art date
Application number
ARP070100239A
Other languages
English (en)
Inventor
James Dodge
Marco A Passini
Lamya Shihabuddin
Seng H Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR059089A1 publication Critical patent/AR059089A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Enfermedades de almacenamiento lisosomal pueden tratarse exitosamente mediante la aplicacion intraventricular de la enzima etiologicamente deficiente en la enfermedad. Para lograr el efecto máximo, la administracion puede realizarse lentamente. Sorprendentemente, se observan efectos en ambos lados de la barrera sangre-cerebro, por lo cual éste es un medio de aplicacion ideal para enfermedades de almacenamiento lisosomal que afectan ambos, el cerebro y organos viscerales.
ARP070100239A 2006-01-20 2007-01-19 Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal AR059089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76037806P 2006-01-20 2006-01-20

Publications (1)

Publication Number Publication Date
AR059089A1 true AR059089A1 (es) 2008-03-12

Family

ID=38288294

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070100239A AR059089A1 (es) 2006-01-20 2007-01-19 Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ARP170102114A AR109170A2 (es) 2006-01-20 2017-07-27 Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170102114A AR109170A2 (es) 2006-01-20 2017-07-27 Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente

Country Status (19)

Country Link
US (4) US8926967B2 (es)
EP (3) EP1984018B1 (es)
JP (1) JP5681345B2 (es)
CN (1) CN101431960A (es)
AR (2) AR059089A1 (es)
BR (1) BRPI0706699A2 (es)
CA (2) CA2636991C (es)
DK (2) DK2666476T3 (es)
ES (2) ES2716206T3 (es)
HU (1) HUE041840T2 (es)
IL (2) IL192740A (es)
LT (1) LT2666476T (es)
MX (1) MX349749B (es)
PL (2) PL1984018T3 (es)
PT (2) PT1984018E (es)
RU (3) RU2529830C2 (es)
SI (2) SI2666476T1 (es)
TR (1) TR201903855T4 (es)
WO (1) WO2007084737A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
MX361816B (es) * 2006-02-09 2018-12-17 Genzyme Corp Suministro intraventricular lento.
US8454954B2 (en) 2007-05-16 2013-06-04 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
PL2889043T3 (pl) * 2008-12-16 2019-09-30 Genzyme Corporation Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
EP2470199B1 (en) * 2009-08-28 2019-05-22 Icahn School of Medicine at Mount Sinai Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
MX338426B (es) 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
CA2805413A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of heparan n-sulfatase
UA115649C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
WO2011163651A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
EP2588130B1 (en) * 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
AU2011270670B2 (en) * 2010-06-25 2017-01-12 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A
ES2896060T3 (es) 2010-06-25 2022-02-23 Shire Human Genetic Therapies Métodos y composiciones para la administración al SNC de arilsulfatasa A
JP2012062312A (ja) * 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
DK2613798T4 (en) * 2010-09-09 2018-04-16 Synageva Biopharma Corp USING LYSOSOMAL SUR LIPASE TO TREAT PATIENTS WITHOUT LYSOSOMAL SUR LIPASE
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
EA201792099A1 (ru) * 2011-12-23 2018-05-31 Шир Хьюман Дженетик Терапис, Инк. Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы
EA039246B1 (ru) * 2012-12-06 2021-12-22 Шир Хьюман Дженетик Терапис, Инк. Способ лечения когнитивных нарушений, связанных с синдромом хантера
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
EP3584580A1 (en) 2013-06-07 2019-12-25 Genzyme Corporation Recombinant human acid sphingomyelinase for use in treating human asmd
EP3450557A1 (en) 2013-12-25 2019-03-06 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
WO2015119989A1 (en) * 2014-02-04 2015-08-13 New York University Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP6914193B2 (ja) 2015-06-24 2021-08-04 Ｊｃｒファーマ株式会社 Ｂｄｎｆを含む融合蛋白質
KR20250073514A (ko) 2015-06-24 2025-05-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
US11390656B2 (en) * 2015-08-04 2022-07-19 New York University Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
RU2634113C1 (ru) * 2016-11-18 2017-10-24 Государственное бюджетное учреждение "Академия наук Республики Саха (Якутия)" (ГБУ АН РС(Я)) Способ фиксации головного мозга ископаемого позднеплейстоценового млекопитающего
CA3052936A1 (en) 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein of bdnf and anti-transferrin receptor antibody
NZ752703A (en) 2016-12-26 2022-09-30 Japan Chem Res Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
PY1939780A (es) * 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
WO2020157248A1 (en) 2019-02-01 2020-08-06 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
RU2723187C1 (ru) * 2019-10-04 2020-06-09 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Генетическая кассета, содержащая кодон-оптимизированные нуклеотидные последовательности генов HEXA и HEXВ, и фармацевтическая композиция для лечения болезни Тея-Сакса
EP4284442A4 (en) * 2021-02-01 2025-04-23 The Trustees of The University of Pennsylvania COMPOSITIONS AND METHODS FOR TREATING NIEMANN PICK DISEASE TYPE A

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
WO1995029993A1 (en) 1994-04-28 1995-11-09 The University Of Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
EP0821739B1 (en) 1995-04-17 2003-06-18 The Board Of Regents, The University Of Texas System An adenovirus helper-virus system
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU1695197A (en) 1996-01-05 1997-08-01 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
PT1538202E (pt) * 1996-09-13 2014-04-22 Shire Human Genetic Therapies Produção de alga-galactosidase a humana
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6702945B2 (en) 2000-12-28 2004-03-09 Exxonmobil Research And Engineering Company Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions
US6689756B2 (en) 2001-03-02 2004-02-10 Integra Lifesciences Corporation Treatment of neurological disease
US20030163181A1 (en) 2001-12-07 2003-08-28 Neuron Therapeutics, Inc. Protection of neurological tissue by direct CNS perfusion cooling
WO2004047768A2 (en) 2002-11-26 2004-06-10 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
CA2518407A1 (en) 2003-03-12 2004-09-23 Samaritan Pharmaceuticals, Inc. Animal model simulating neurologic disease
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
AU2004253471B2 (en) 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1730183A2 (en) 2004-01-27 2006-12-13 Compugen USA, Inc. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005095955A1 (en) 2004-03-31 2005-10-13 Children, Youth And Women's Health Service Screening for lysosomal storage disease status
WO2005099748A1 (de) * 2004-04-13 2005-10-27 Cilian Ag Rekombinante lysosomale enzyme mit ciliaten-typischem glykosylierungsmuster für die therapie
US8889127B2 (en) * 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
AR059088A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
MX361816B (es) * 2006-02-09 2018-12-17 Genzyme Corp Suministro intraventricular lento.
PT3252161T (pt) 2007-06-06 2022-02-01 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal

Also Published As

Publication number Publication date
EP1984018A2 (en) 2008-10-29
LT2666476T (lt) 2019-04-10
PL2666476T3 (pl) 2019-06-28
BRPI0706699A2 (pt) 2011-04-05
ES2526710T3 (es) 2015-01-14
PT2666476T (pt) 2019-03-28
IL192740A0 (en) 2009-02-11
CA2966155A1 (en) 2007-07-26
DK2666476T3 (en) 2019-04-08
EP2666476A1 (en) 2013-11-27
EP1984018B1 (en) 2014-10-01
PT1984018E (pt) 2014-10-22
ES2716206T3 (es) 2019-06-11
IL250937A0 (en) 2017-04-30
IL192740A (en) 2017-11-30
EP2666476B1 (en) 2018-12-19
US20090130079A1 (en) 2009-05-21
RU2018129747A (ru) 2020-02-19
CA2636991C (en) 2017-07-04
SI1984018T1 (sl) 2014-11-28
SI2666476T1 (sl) 2019-04-30
RU2014129319A (ru) 2016-02-10
PL1984018T3 (pl) 2015-04-30
RU2665381C2 (ru) 2018-08-29
JP2009525963A (ja) 2009-07-16
TR201903855T4 (tr) 2019-04-22
CA2636991A1 (en) 2007-07-26
JP5681345B2 (ja) 2015-03-04
EP3517124A1 (en) 2019-07-31
US20190083582A1 (en) 2019-03-21
DK1984018T3 (da) 2014-11-03
RU2008134120A (ru) 2010-02-27
MX349749B (es) 2017-08-10
CN101431960A (zh) 2009-05-13
US20210228692A1 (en) 2021-07-29
US20150313970A1 (en) 2015-11-05
WO2007084737A2 (en) 2007-07-26
US10080783B2 (en) 2018-09-25
EP1984018A4 (en) 2010-07-21
WO2007084737A3 (en) 2008-10-23
US8926967B2 (en) 2015-01-06
RU2529830C2 (ru) 2014-09-27
AR109170A2 (es) 2018-11-07
HUE041840T2 (hu) 2019-05-28

Similar Documents

Publication Publication Date Title
MX349749B (es) Suministro enzimatico intraventricular para enfermedades de almacenamiento lisosomico.
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
MX2018013333A (es) Composiciones de nucleasas terapeuticas y metodos.
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
WO2008022349A3 (en) Agents for blood-brain barrier delivery
MX2009006651A (es) Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
WO2010059253A3 (en) Methods and compositions for localized agent delivery
EA201101523A1 (ru) Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
EA201071059A1 (ru) Способы и композиции для лечения воспаления и связанных с воспалением патологических состояний
BR122020010601B8 (pt) conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
WO2009135178A3 (en) Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2009149106A3 (en) Microparticles for the treatment of disease
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal

Legal Events

Date Code Title Description
FC Refusal